VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Linda J Paradiso, DVM
Vitrac Therapeutics, LLC
Study Director - Sarah Goldberg, MD, MPH
Yale Cancer Center, Yale University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California Davis
Sacramento, California, United States
- Yale Cancer Center
North Haven, Connecticut, United States
- Emory University Winship Cancer Center
Atlanta, Georgia, United States
- University of Maryland Cancer Center
Baltimore, Maryland, United States
- New York University Langone Health Perlmutter Cancer Cancer
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Nov 2022
- Primary completion
- 26 Aug 2023
- Completion
- 26 Aug 2023
- Last update posted
- 1 May 2025
- Registered enrollment
- 3
- Registry id
- NCT05374538
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.